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SUMMARY 
Background: Hepatocyte apoptosis, the hallmark of Non-alcoholic steatohepatitis (NASH) 
contributes to liver injury and fibrosis. Although, both the intrinsic and extrinsic apoptotic 
pathways are involved in the pathogenesis of NASH, the final common step of apoptosis is 
executed by a family of cysteine-proteases termed caspases.  
Thus, our aim was to ascertain if administration of Emricasan, a pan-caspase inhibitor, 
ameliorates liver injury and fibrosis in a murine model of NASH. Methods: C57/BL6J-mice 
were fed regular chow or high fat diet (HFD) for 20 weeks. All mice were treated with 
vehicle or Emricasan.  
Results: Mice fed a HFD diet demonstrate a 5-fold increase in hepatocyte apoptosis by the 
TUNEL assay and a 1.5-fold and 1.3-fold increase in caspase-3 and-8 activities respectively; 
this increase in apoptosis was substantially attenuated in mice fed a HFD treated with 
Emricasan (HFD-Em).  Likewise, liver injury and inflammation were reduced in mice fed 
HFD-Em as compare to HFD by measuring serum AST and ALT levels, NAS histologic score 
and IL 1-β, TNF-α, MCP-1 and CXCL2 qPCR. These differences could not be attributed to 
differences in hepatic steatosis as liver triglycerides content were similar in both HFD 
groups. Hepatic fibrosis was reduced by Emricasan in HFD animals by decreasing αSMA (a 
marker for HSC activation), fibrosis score, Sirius red staining, hydroxyproline liver content 
and profibrogenic cytokines by qPCR.  
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In Conclusion, these data demonstrate that in a murine model of NASH, liver injury and 
fibrosis are suppressed by inhibiting hepatocytes apoptosis and suggests that Emricasan 
may be an attractive anti-fibrotic therapy in NASH  
 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is currently the most common form of chronic 
liver disease, affecting 20-30 % of western countries population 1, and is closely associated 
with insulin resistance (IR) and overweight 2. A subset of these individuals, approximately 
5%, develops hepatic inflammation and fibrosis, a syndrome referral as nonalcoholic 
steatohepatitis (NASH) 3. This hepatic inflammatory disorder can progress to cirrhosis, 
liver failure, and hepatocellular carcinoma 4. The mechanisms underlying the progression 
of simple steatosis to steatohepatitis are not known; however, it is recognized that 
hepatocyte apoptosis correlates with NASH. Indeed, apoptosis is a cardinal pathological 
feature of NASH and is associated with hepatic inflammation and fibrosis 5. Consistent 
with this concept, elevated serum cytokeratin-18 fragments (M30 Neo-epitopes), markers 
of hepatocyte apoptosis by caspase activation, distinguish simple hepatic steatosis from 
NASH 6.  
Apoptosis, or programmed cell death, is a form of highly regulated cell death. Steatotic 
hepatocytes can undergo apoptosis via an extrinsic pathway activated by death ligands, 
Fas 5 7 and tumor necrosis factor related apoptosis inducing ligand (TRAIL) 8 9 10 or via 
activation of the intrinsic pathway 11 12, which can be triggered by intracellular stress of 
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membrane-bound organelles, such as lysosomes 13, endoplasmic reticulum (ER) 14, and 
mitochondria 11. Both pathways of apoptosis converge on caspases activation which 
makes this pathway mechanistically attractive by pharmacological inhibition. This group of 
proteases, term caspases (cysteinyl aspartate specific proteases), play a central role as 
executors of apoptosis. The caspases are constitutively expressed as inactive proenzymes 
and generally require proteolytic cleavage on the aspartic acid residue for their activation. 
Caspases are capable of self activation, as well as of activating each other in a cascade-like 
process. Among the 14 mammalian caspases identified to date, some are primarily 
involved in apoptosis (caspases-2, -3, -6, -7, -8, -9, -10, and -12) 15, and other caspases, 
such as caspases-1, -4, -5, and -11, are involved in inflammation 16. These caspases can be 
divided into initiator caspases or effector caspases. Initiator caspases (-2, -8, -9, -10) that 
are activated by death receptors; and effector caspases (-3, -6, and -7) that require 
cleavage by initiator caspases for their activation 17. On initiation of apoptotic cascades, 
activation of initiator caspases occur causing mitochondria dysfunction, with release of 
proapoptotic factors into the cytosol (e.g., cytochrome c, SMAC/Diablo, endonuclease G 
and AIF) 18. Cytosolic cytochrome c promotes activation of downstream effector caspases, 
cleavage of cellular targets and dismantle the cell causing characteristic apoptotic 
morphology. These apoptotic bodies are phagocytosed by adjacent cells, and it has been 
demonstrated that phagocytosis of apoptotic bodies by Kuppfer cells 19 and hepatic 
stellate cells (HSC) 20 is one of the mechanisms that promote inflammation and 
fibrogenesis. Based on this concept, decreasing hepatocytes apoptosis by caspases 
inhibitors protects the liver in murine models of acute liver failure 21, and attenuates 
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inflammation and fibrosis in murine models of cholestatic- 22, ethanol- 23 and 
methionie/choline deficient diet-induced 24 25 liver injury. Thus, the use of a pan-caspase 
inhibitor could be an attractive therapeutic approach for various types of liver disease. 
However, its efficacy for long term treatment such as NASH merits further evaluation.  
Emricasan (IDN-6556) is an irreversible pan-caspase inhibitor, orally active that is retained 
in the liver for prolonged period of time 26 21, which was evaluated in clinical trials for 
chronic liver disease 27 28. Therefore, in this study, we examined the effect of the pan-
caspase inhibitor emricasan on liver injury and fibrosis in a diet induced metabolic 
syndrome with NASH murine model. To address our aim, we formulated the following 
questions: Does the pan-caspase inhibitor … 1) attenuate hepatocyte apoptosis and liver 
injury?, 2) reduce hepatic steatosis?, 3) decrease hepatic inflammation?, and 4) attenuate 
hepatic fibrogenesis in diet induced NASH model?. The results demonstrate that in a 
murine model of NASH, liver injury and fibrosis are attenuated by inhibiting hepatocytes 
apoptosis and suggest that emricasan may be an attractive anti-fibrotic therapy in NASH.  
 
EXPERIMENTAL PROCEDURES  
Reagents and diet: Sucrose, Direct red 80 and Fast-green FCF (color index 42053) were 
obtained from Sigma. Emricasan (formerly named IDN-6556 or PF-03491390), was 
provided by Pfizer Ltd., was suspended in vehicle [2% (v/v) DMSO in 0.5% (w/v) 
methylcellulose] and administered to mice per os daily. The high fat diet used was from 
Cathedra of Bromatology, Faculty of Pharmacy and Biochemistry, University of Buenos 
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Aires (Cátedra de Bromatología. Facultad de Farmacia y Bioquímica. Universidad de 
Buenos Aires), which contains 47% of calories from fat (mostly from Milk fat, 50% 
saturated fat) with 2% of cholesterol, 35% from carbohydrate (78% of carbohydrate from 
Sucrose) and 18% of calories from protein, and was designed to approximate the typical 
human diet from patients with NASH 29 30.  
 
Animals. Studies were performed in male C57BL/6J mice (Bioterio Central, Facultad de 
Ciencias Exactas y Naturales, Universidad de Buenos Aires). All animals were maintained in 
a temperature (24°C) and light controlled (12:12 hr light:dark) facility, and had free access 
to food and water. Animals were age-matched and used at approximately 12-16 weeks of 
age. Four groups were studied (n = 60) with 15 mice per group. Groups 1 and 3 received 
regular chow. Groups 2 and 4 received high fat diet and 50 g/L (Sucrose) was added to 
drinking water for 20 weeks. Groups 3 and 4 received Emricasan 0.3mg/kg/day i.g., and 
group 1 and 2 received the vehicle. The dosing was based on previous data 21 that 
demonstrates that oral administration of emricasan at doses of 0.3 mg/kg corresponded 
to the ED90 value to prevent liver injury in the model of α-Fas-induced liver injury. Total 
body weight was measured at 0, 5, 10, 15 and 20 weeks. All protocols dealing with animals 
were reviewed and approved by the University of Buenos Aires Animal Studies Committee 
(CICUAL, Comité Institucional de Cuidado y Uso de Animales de Experimentación). This 
study followed the guidelines outlined in the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. 
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Serum and Tissue Analysis. Blood samples and liver tissue were collected under deep 
anesthesia after a 8-h fast. Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), glucose and cholesterol levels were measured using Roche-
Hitachi 911 Chemistry Auto-Analyzer. Plasma insulin was measured using a mouse insulin 
enzymelinked immunosorbent assay kit (Milipore). Insulin resistance was calculated using 
the homeostasis model assessment of insulin resistance (HOMA-IR) 31. Whole liver were 
homogenized in 1 mL of cold lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 2.5 mM ethyleneglycol tetraacetic acid [EGTA], 1 
mM dithiothreitol, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride [PMSF], 10 μg/mL 
each of aprotinin and leupeptin, 50 mM NaF and 0.1 mM sodium orthovanadate) per 100 
mg of tissue 32. Homogenates were clarified by centrifugation at 10,000g for 10 minutes at 
4°C and stored at -70°C. Thiobarbituric acid reactive substances (TBARS) assay were 
measured to quantify lipid peroxidation and tissue oxidative stress in whole liver 
homogenate using a colorimetric assay as described by Ohkawa et al 33. Commercial ELISA 
kits were used to measure hepatic levels of TNF-alpha (Mouse TNF-α ELISA Kit, EZMTNFA, 
Milipore) and MCP-1 (Mouse MCP-1 Elisa kit, RAB0056, Sigma) following the 
manufacturers’ instructions. Hepatic lipid content was analyzed for total triglycerides (TG) 
and cholesterol, briefly, frozen liver tissue (100 mg) was homogenized in 1.6 ml 
phosphate-buffered saline and protein concentration was determined using Bradford 
Protein Assay (Bio-Rad). Lipid was extracted using chloroform:methanol (2:1) and 0.1% 
sulfuric acid as described 34. An aliquot of the organic phase was collected, dried with 
chloroform containing 1% Triton, and resuspended in water (final Triton concentration = 
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~2%). TG content was determined using commercially available kits (Wako Chemicals) in 
microtiter plates and normalized to protein concentration of the homogenate. The hepatic 
lipid concentration was expressed as μg of TG/mg of liver protein.  
 
Terminal Deoxynucleotidyl Transferase–Mediated dUTP Nick-End Labeling (TUNEL) 
Assay. Tissue sections (5 μm) were prepared, and terminal deoxynucleotidyl transferase 
dUTP nick-end labeling (TUNEL) assay was performed following manufacturer’s 
instructions (ApopTag Fluorescein In Situ Apoptosis Detection Kit, Chemicon). Apoptotic 
cells were quantified by the TUNEL assay, which enzymatically labels free 3′-OH ends of 
damaged DNA with a fluorescently labeled nucleotide as we have previously described in 
detail35. TUNEL-labeled cells (that is, fluorescent nuclei) were quantified by the number of 
positive cells per high-power field being counted. A total of 10 high-power fields were 
analyzed for each animal, using Nikon Eclipse E800 microscope (Nikon, Melville, NY) 
coupled to a Nikon DN100 CCD camera. Data were expressed as the number of TUNEL-
positive cells per 10 high-power fields.  
 
α-Smooth Muscle Actin Staining. Livers were dissected and processed for paraffin 
inclusion. Five micron-thick sections of formalin-fixed, paraffin-embedded liver were used 
for α-SMA immunofluorescence staining. Slides were deparaffinized in xylene and serially 
rehydrated in graded ethanol (100 to 70%). Endogenous peroxidase was quenched with 
0.5% hydrogen peroxide in 90% ethanol for 20 min. Prior to primary antibody incubation, 
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endogenous avidin and biotin were blocked for 20 min using the Vector Laboratories 
blocking kit and unspecific binding of the antibody was subsequently blocked for 30 min in 
1% BSA in PBS. Tissue was incubated overnight with a mouse monoclonal Cy3-coupled 
anti-smooth muscle actin antibody (αSMA; 1/200; Sigma). After extensive washing, 
sections were coverslip-mounted for microscopic observation. As technical control, 
incubation with primary antibody was omitted rendering no significant staining. Pictures 
were taken using a Nikon DN100 CCD camera coupled to a Nikon Eclipse 800 fluorescence 
microscope. Quantitative analysis of immunohistochemical staining of αSMA was 
performed by computerized morphometric analysis (CMA). Approximately 100-200 
microscopic field (x400) per specimen were captured and analyzed using a color threshold 
detection system developed in Matlab 6.0 (Mathworks,Inc, USA). The results obtained 
were expressed as unit of αSMA positive area per field.  
 
Assessment of Liver Fibrosis. Liver fibrosis was semiquantified using Sirius red staining as 
described by Camino et al 36. Liver sections were stained with picrosirius red staining, and 
red-stained collagen fibers were quantified by computerized morphometric analysis 
(CMA). For CMA whole liver samples were analyzed with the excepetion of large 
centrilobular veins and large portal tract (≥ 150 μm). Two hundred light microscope 
images per speciem were captured and analyzed using color threshold detection system 
(Matlab 6.0, Mathworks,Inc, USA). The results were expressed as a percentage of positive 
area.  
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Additionally, collagen deposition was measured by hydroxyproline assay as detailed 
previously 36. Briefly, hydroxyproline content was quantified colorimetrically in duplicate 
from 0,2 g liver sample at 557 mm from a standard curve the amino acid alone and against 
a blank reagent. The results were expressed as mg/g of liver tissue.  
 
Histopathology. For histological review of hematoxylin and eosin (H&E)–stained liver 
sections by light microscopy (Eclipse, Nikon), the liver was fixed in 10% formalin buffer, 
and then embedded in paraffin. Tissue sections of 5-μm-thick were prepared and placed 
on glass slides. H&E and Mallory Trichrome staining were performed according to 
standard techniques. The slides were coded, without the pathologist knowing the specific 
treatment group that the slides represented. The histology was graded according to a 
number of histological features. Steatohepatitis was assessed using NAFLD activity score 
by the modified semiquantitative Brunt score 37. This measures degree of steatosis (0=  
<5%; 1: 5%-33%; 2= 33%-66%; 3= >66%), inflammation (0= no foci; 1= <2 foci per 200x 
field; 2= 2-4 foci per 200x field; 3= >4 foci per 200x field), and hepatocyte ballooning 
degeneration (0= none; 1= few balloon cells; 2= many cells/prominent ballooning). 
Fibrosis was determined by the following scale, 0= none; 1= zone 3 only, perisinusoidal; 2= 
zone 2-3, perisinusoidal; 3= perisinusoidal and portal/periportal; 4= bridging fibrosis; 5= 
cirrhosis.  
Analysis of Caspase Activation. For detection of the active form of caspases-3 and -8, 
colorimetric protease assay kits (Chemicon International, Inc.) were used. Proteins 
obtained from cytosolic extracts from liver tissue (100 μg) and were incubated with 200 
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μM DEVD-pNA (for caspase-3) or IETD-pNA (for caspase-8), The assay was based on the 
spectrophotometric detection of the chromophore p-nitroanilide (pNA) after cleavage 
from the labeled substrates. p-NA light emission was quantified using a microtiter plate 
reader at 405 nm. Comparison of the absorbance of p-NA from HFD fed mice samples with 
regular chow fed mice allowed determination of the-fold increase in caspase activity 38, 
samples were evaluated in triplicate each.  
 
Real-Time Polymerase Chain Reaction. Total RNA was extracted from liver tissue using 
the Trizol Reagent (Invitrogen), and was reverse-transcribed into complementary DNA 
with Moloney leukemia virus reverse transcriptase and random primers (both from 
Invitrogen). Quantification of the complementary DNA template was performed with real-
time polymerase chain reaction (PCR) (Mx3000P QPCR thermocycler, Stratagene) using 
SYBR green (Invitrogen) as a fluorophore. PCR primers (all obtained from Invitrogen) were 
as follows: murine αSMA Forward: 5′-ACT ACT GCC GAG CGT GAG AT-3′,  Reverse: 5′-AAG 
GTA GAC AGC GAA GCC AG-3′; murine Collagen1-α Forward: 5′-GAA ACC CGA GGT ATG 
CTT GA-3′, Reverse: 5′-GAC CAG GAG GAC CAG GAA GT-3′; murine Interleukin-1β Forward: 
5′- GCC CAT CCT CTG TGA CTC AT-3′, Reverse:  5′-AGG CCA CAG GTA TTT TGT CG-3′; 
murine CHOP Forward: 5′- CTG CCT TTC ACC TTG GAG AC-3′, Reverse: 5′-GGA CGC AGG 
GTC AAG AGT AG-3′;  murine TGF-β Forward: 5′- CTC CCG TGG CTT CTA GTG C-3′, Reverse: 
5′-GCC TTA GTT TGG ACA GGA TCT G-3′, murine TNF-α: Forward 5′- CCC TCA CAC TCA GAT 
CAT CTT CT-3′, Reverse: 5′-GCT ACG ACG TGG GCT ACA G-3′; murine TIMP-1: Forward 5′- 
CAT GGA AAG CCT CTG TGG ATA TG-3′, Reverse: 5′-GAT GTG CAA ATT TCC GTT CCT T-3′; 
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murine CXCL-2: Forward 5′-CTC TCA AGG GCG GTC AAA AAG TT-3′, Reverse: 5′-TCA GAC 
AGC GAG GCA CAT CAG GTA-3′; murine MCP-1: Forward 5′- CTT CTG GGC CTG CTG TTC A-
3′, Reverse: 5′-CCA GCC TAC TCA TTG GGA TCA-3′. As an internal control, primers from 
murine β-Actin were used as follow: Forward: 5′- TTC TAC AAT GAG CTG CGT GT-3′, 
Reverse: 5′-CTC TCA GCT GTG GTG GTG AA-3′. After electrophoresis in 1,5% agarose gel, 
each expected base pair PCR product was cut out and eluted into Tris-HCl using a DNA 
elution kit (Gel extraction kit; Quiagen). The concentrations of extracted PCR products 
(copies per microliter) were measured using a spectrophotometer at 260 nm and were 
used to generate standard curves. The inverse linear relationship between copy and cycle 
numbers was then determined. Each resulting standard curve was then used to calculate 
the number of copies per microliter in experimental samples. The relative expression level 
of each product was expressed as a ratio of β-Actin copies of PCR Product for each sample. 
Data were expressed as fold change from regular chow fed mice.  
 
Statistical Analysis. All data represent are expressed as the mean ± 95% CI for mean, or 
otherwise indicated.  Differences between groups were compared by an ANOVA analysis 
followed by a post-hoc Student-Newman–Keuls test, parametric test or the Kruskall–
Wallis nonparametric test. Differences were considered to be statistically significant at 
P<0.05.  
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RESULTS  
Is Liver injury attenuated in Emricasan treated HFD fed mice?    
We first examined the effects of the pan-caspase inhibitor Emricasan on hepatocyte 
apoptosis in C57BL/6J mice fed a high fat diet. Hepatocyte apoptosis was assessed by 
TUNEL assay and caspase -3 and -8 activities were evaluated to determine the efficiency of 
the pharmacological caspase inhibition by emricasan (Figure 1). TUNEL positive cells were 
considerably increased by 5 fold in mice fed a HFD and were reduced under emricasan 
treatment (Figure 1 A, and B). In accordance with this observation caspase -3 and -8 were 
increased in HFD-fed mice by 1.5 and 1.3 fold respectively and were significantly 
decreased by emricasan treatment (Figure 1 C and D). To further evaluate the effects of 
the pan-caspase inhibitor in reducing liver injury, we next examined liver histology score, 
serum AST and ALT values in HFD fed mice treated with vehicle or emricasan. 
Histopathologic examination of liver specimens demonstrated increased histological 
parameters of liver injury as assessed by NAFLD activity score (NAS) in the mice fed a HFD 
(Figure 2). In accord with this observation, serum AST and ALT were 3-5 fold higher in HFD 
than regular chow-fed mice, and the emricasan treated group showed a significant 
decrease in AST and ALT serum levels (Figure 3 A and B). Also, Lipid peroxidation was 
assessed as a surrogate for hepatic oxidative stress-mediated liver injury. Significantly 
higher levels of TBARS were detected in HFD-fed animals compared to regular chow diet, 
and the emricasan treatment significantly reduced TBARS (Figure 3 C). 
Next we evaluated the effect of emricasan on features of metabolic syndrome and hepatic 
steatosis. Mice fed a HFD had significantly increased weights, associated with 
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hyperglycemia, hyperinsulinemia and hypercholesterolemia as compared with regular 
chow-fed mice (Table 1). Moreover, HFD-fed mice had dramatically induced fat 
accumulation, increasing the score of steatosis (Figure 2) and hepatic content of 
triglycerides and cholesterol (Table 1). Treatment with emricasan did not significantly 
impact features of metabolic syndrome, insulin resistance or hepatic steatosis. 
Collectively, these data indicate a pathogenic role for caspase-mediated hepatocyte 
apoptosis in liver injury in a NASH murine model and demonstrate that the pan-caspase 
inhibitor emricasan decreases liver injury but not metabolic derangement in NASH.  
 
Is hepatic inflammation reduced in Emricasan-treated HFD-fed mice?  
To examine the changes of hepatic inflammation in HFD fed mice under Emricasan 
treatment, key mediators of inflammation (TNF-α, IL-1β), monocyte and neutrophil 
infiltration (MCP-1, CXCL2) were quantitated at protein level and messenger RNA 
transcripts using qPCR. In HFD fed mice, the inflammatory mediators TNF-α, IL-1β, MCP-1 
and CXCL2 were significantly increased compared with Emricasan-treated HFD fed animals 
(Fig. 4, A, B, C, D, E and F). Consistent with these results, histological examination of 
inflammation score demonstrated a clear decrease in inflammatory foci in emricasan-
treated mice compared with vehicle-treated HFD fed mice (Reg Chow: 0.3 ± 0.1, HFD: 2.2 
± 0.2*, HFD-Emricasan: 0.6 ± 0.2, * p<0.05 ) (Figure 2). Indeed the overall NAS score 
showed a protective effect by emricasan treatment (Reg Chow: 0.5 ± 01, HFD: 6.1 ± 0.3, 
HFD + Emricasan: 3.2 ± 0.4) (Figure 2). Such differences cannot be attributed to 
differences in hepatic steatosis as hepatic triglyceride content was similar in both groups 
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(Table 1). Therefore, these data demonstrate that inflammation is coupled to caspase-
dependent liver injury in HFD-diet induced NASH and the treatment with the pan-caspase 
inhibitor ameliorates inflammation and liver injury.  
 
Is hepatic fibrogenesis attenuated in Emricasan treated HFD fed mice?  
To investigate if the reduction in liver injury in HFD-fed mice with Emricasan is significant, 
it should also translate into reduced hepatic fibrogenesis. Because phagocytosis of 
apoptotic bodies promotes myofibroblastic transformation of HSC, we next evaluated α-
SMA expression, an established marker for HSC activation in NASH 39, by quantifying 
mRNA transcripts with qPCR analysis. In HFD-fed animals, α-SMA mRNA transcripts were 
significantly increased compared with regular chow group, indicating HSC activation in 
NASH (Figure 5 A). In contrast, the transcripts for α-SMA were significantly reduced by 
80% in Emricasan-treated HFD-fed animals compared with vehicle-treated HFD mice 
(Figure 5 A). These results were confirmed at the cellular level by performing α-SMA 
immunohistochemistry. Consistent with the mRNA data, the number of α-SMA-positive 
cells was increased along hepatic sinusoid lining cells in HFD-fed mice, and was 
dramatically reduced in drug-treated HFD mice and was confirmed by morphometric 
analysis (Figure 5 B and C). To ascertain whether other markers for HSC activation were 
also reduced in emricasan-treated HFD mice, transcripts for molecules implicated in 
fibrogenesis were quantified. TGF-β and TIMP-1, pivotal cytokines in promoting 
fibrogenesis, were also increased in HFD animals versus Emricasan-treated HFD mice 
(Figure 6 A and B).  
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To determine if the reduced α-SMA expression was accompanied by changes in liver 
fibrosis, collagen-1α (I) mRNA expression, the principal form of collagen in hepatic 
cirrhosis, was determined using qPCR techonology. Indeed, collagen-1α was clearly 
increased by 5-fold in HFD-fed mice versus Emricasan-treated mice (Figure 7 B). 
Furthermore, liver specimens were analyzed by Mallory´s trichrome and collagen 
deposition was stained using Sirius red and quantitated by digital image analysis (Figure 7 
A). Liver histology evaluation by Mallory´s trichrome observed evidence of perisinusoidal 
and pericellular fibrosis in HFD animals, as expected in NASH; in comparision, the amount 
of fibrosis was significantly reduced in HFD-fed mice treated with Emricasan (Modified 
fibrosis score: HFD: 2,3±0,3 Vs HFD-Emricasan: 0,3±0,2, p<0,001), and no fibrosis was 
observed in regular chow fed mice (Figure 7 A and C). Sirius red staining showed 
significant collagen staining like “chicken wire” along sinusoids (perisinusoidal) and around 
hepatocytes (pericentral) in HFD-fed mice; however, the quantity of collagen was again 
significantly reduced in Emricasan-treated mice (Figure. 7 A and D). Accordingly, the 
biochemical assessment of hydroxyproline showed a marked increase in the mean 
hydroxyproline levels by 8-fold in HFD-fed animals than in the Emricasan-treated mice 
(Figure 7 E). Collectively, these observations suggest that, in the murine NASH model, 
stellate cell activation and hepatic fibrogenesis are attenuated by administration of the 
pan-caspase inhibitor Emricasan.  
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DISCUSSION  
The principal findings of this study pertain to the role of caspase inhibition as a 
therapeutic pharmacological target in a murine model of metabolic syndrome with NASH. 
We demonstrate that prolonged pharmacological inhibition of caspases has a beneficial 
effect in NASH by reducing hepatocyte apoptosis and decreasing liver injury, hepatic 
inflammation and markedly reducing HSC activation and fibrogenesis. Together these 
observations suggest caspase activation has a clear pathogenic role in NASH and a 
treatment that inhibits hepatocyte apoptosis might limit hepatic injury and attenuate 
progression of fibrosis in NASH, a highly prevalent disease with no effective 
pharmacological therapy.  
In this study we used a high fat diet that recapitulates the clinical findings in human NASH 
such as obesity and insulin resistance 29 30. This diet also was enriched in fructose and 
cholesterol, two key components of the western diet induced NASH 40 41 that are 
associated with liver injury 42 43, inflammation 44 45 and fibrosis 46 47. Moreover, in our 
study the histopathological analysis of the liver specimens from HFD-fed mice depicts the 
characteristic features of NASH which are para-acinar steatosis, cellular ballooning, acinar 
inflammation, hepatocyte apoptosis, peri-sinusoidal and peri-celluar fibrosis 48 5. Thus, our 
diet induced NASH is a useful tool to examining therapeutic approaches during metabolic 
disturbances.  
Apoptosis has been implicated as cardinal feature of non-alcoholic fatty liver disease by 
serological markers and liver tissue analysis, where it correlates with histological severity 
and fibrosis progression 5 6. Hepatocyte apoptosis in vitro and in murine models of 
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steatohepatitis is mediated in part by the activation of the extrinsic pathway of apoptosis 
by death receptor Fas 49 5 and TRAIL-DR4/TRAIL-DR5 8 9 10, that can be activated by their 
ligands but also the toxic saturated fatty acid palmitate can activate TRAIL-DR5 by 
clustering 50 and augment the FADD-recruitment and caspase-8 activation of Fas by 
palmitoyltation 51. In vitro studies demonstrate that free fatty acids induce hepatocyte 
apoptosis by activation of the intrinsic pathway; the saturated fatty acids trigger ER stress-
associated JNK and CHOP activation engage apoptosis by enhancing expression and 
function of pro-apoptotic members of the Bcl-2 family, PUMA 12 52 and Bim 53 54. Both 
apoptotic pathways converge on caspase activation to induce cell death, and based on this 
concept the use of pharmacological inhibition of caspase is a useful tool to reduce 
hepatocyte apoptosis. In this study we demonstrate a significant increase in hepatocyte 
apoptosis and caspase activation in the NASH model of HFD-fed mice, and the treatment 
with emricasan, a pan-caspase inhibitor, abrogates liver cell apoptosis and caspase 
activation evaluated by TUNEL assay and caspase-3 and -8 activities. Our observations 
support previous in-vitro studies that showed FFA mediated cytotoxicity was completely 
blocked by a pan-caspase inhibitor 11 and a NASH clinical trial where use of the caspase 
inhibitor GS-9450 decreased cytokeratin-18 fragments, a serum marker of hepatocytes 
apoptosis 55.   
In liver, hepatocyte apoptosis has been linked to inflammation and fibrogenesis. The 
mechanisms by which apoptosis promotes inflammation relate to the engulfment of 
apoptotic bodies by monocyte/macrophage resident cells (Kupffer cells), engaging their 
activation and expression of death ligands (TNF-α, TRAIL and FasL) 19, pro-inflammatory 
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cytokines and chemokines 56. These recruit and activate inflammatory cells that may 
further aggravate liver inflammation, what is called the second phase of injury. In contrast 
to a decreased liver injury, we failed to observe a reduction in hepatic steatosis. This is not 
unexpected, since triglyceride synthesis has been suggested as a protective mechanism 
against lipotoxicity 57. Indeed, these observations is in accord with Anstee et al 25 that 
using a mice fed a high fat diet under the pan-caspase inhibitor VX-166 showed a marked 
decreased in hepatocyte apoptosis with no effect on liver steatosis, also in a NASH clinical 
trial 55 no effect was observed in parameters associated with metabolic syndrome using a 
pan-caspase inhibitor GS-9450. Our study is consistent with an anti-inflammatory effect of 
pan-caspase inhibitor treatment. In mice fed a HFD we observed a clear inflammatory 
milieu, with increased inflammatory foci in liver specimens, oxidative stress and elevated 
level of pro-inflammatory cytokines TNF-α and IL1-β, and chemokines CXCL2 and MCP-1. 
The pan-caspase inhibitor abrogates the induction of the pro-inflammatory cytokines and 
chemokines by HFD, and markedly reduced the inflammatory score of liver sections. 
Possibly, this phenomenon could be associated with inhibition of pro-inflammatory 
caspases, like caspase-1, -4, -5 and -11. In this way, recent data support a pro-
inflammatory effect of caspase-1 in diet induced NASH 58; in this work murine casp-1 -/- 
showed a decreased expression of pro-inflammatory cytokines, however there was no 
effect on hepatocyte apoptosis or serum aminotransferase levels. The current study 
extends this observation by demonstrating a reduction of aminotransferase and 
hepatocyte apoptosis under pan-caspase therapy in diet induced NASH. Also, our results 
support the data of Csak et al 59, that used an in-vitro model of free fatty acids induced 
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cytotoxicity, where a pan-caspase inhibitor decreased IL1-β production and 
inflammasome activation of steatotic hepatocytes. Perhaps, blocking pro-apoptotic 
caspases would have a hepatocyte-cytoprotective effect and inhibition of pro-
inflammatory caspases might prevent the second phase of injury. Future investigation will 
be necessary to elucidate the biological and clinical importance of each caspase in the 
pathogenesis and therapy of NASH. 
 
Recently the importance of adipokines in the development of hepatic steatosis and 
steatohepatitis has been recognized 60. Adipokines are polypeptides secreted in the 
adipose tissue in a regulated manner. Changes in levels of leptin, adiponectin, visfatin, 
resistin and TNF have been linked to the development of insulin resistance, obesity, and 
liver steatosis; an imbalance in these factors could potentially contribute to the initiation 
and progression of fatty liver disease 61. It is beyond the scope of this work to address the 
impact of caspase inhibition on adipokines levels. However recent data from Dixon et al 
have shown that total body adipose volumes were increased in Casp1-/- mice on the high 
fat diet to a greater extent than wild-type mice. Indeed subcutaneous adipose, rather than 
visceral adipose tissue, is increased in Casp1-/- mice on high fat diet 62. Perhaps, these 
shifts in adipose accretion to subcutaneous adipose tissue could modulate adipokines 
levels and may protect from diet-induced steatohepatitis in caspase1-deficient mice.   
As previously reported 22 24, this study demonstrates that pan-caspase inhibitor treatment 
improved hepatic fibrogenesis. Witek et al, using the obese leptin receptor deficient db/db 
mice fed methionine/choline-deficient diet (MCD) for 8 weeks under pan-caspase inhibitor 
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VX-166 showed a marked decrease in HSC activation and fibrosis. Canbay et al 22, reported 
in a murine model of cholestasis, using bile duct ligation (BDL), a marked reduction in HSC 
activation and collagen-1α deposition. Our study, using a HFD induced NASH with 
prolonged emricasan treatment, demonstrated a significant inhibition of HSC activation, 
reduced pro-fibrogenic cytokine expression, and marked improvement in fibrosis by 
reduced collagen-1α deposition and hydroxyproline liver content. The mechanism 
involved in this anti-fibrotic effect perhaps is related to the anti-inflammatory and anti-
hepatocyte apoptotic effect offered by pan-caspase inhibition. In this way, by reducing 
apoptotic bodies and decreasing the secondary inflammatory response, HSC activation is 
abolished and liver fibrosis prevented. The limits of the present study pertain to the 
experimental model used; we administered emricasan in conjunction with the HFD, 
leaving the question if the previously deposited collagen could be improved or not in well 
established fibrosis. One possibility is that emricasan, by limiting further injury, prevents 
inflammatory cell recruitment/activation, decreases the expression of TIMP-1, promotes 
HSC apoptosis and enhances matrix resorption 63 64 65. Additional studies using models of 
chronic fibrosis and cirrhosis will be necessary to evaluate the effects of Emricasan in 
established fibrotic models. 
Although long-term use of antiapoptotic agents raises the theoretical concern of increased 
risk of neoplastic transformation, this is unlikely. Whereas physiologic apoptosis helps 
protect from cancer, excessive apoptosis might, at least in some experimental situations, 
enhance neoplastic transformation 66. This was depicted by Weber et al, in mice lacking 
the a anti-apoptotic factor myeloid cell leukemia-1 (Mcl-1), have increased apoptosis, cell 
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turnover, which translates into development of malignant HCC-like lesions 67. Also, in the 
transgenic mice that over expressed Bcl-2 in the liver, HCC was prevented in transforming 
growth factor-alpha-induced genetic mouse model of HCC 68. Consistent with this data, 
deletion of proapoptotic BH-3-only protein PUMA protect against diethyl nitrosamine 
(DEN) induced liver cancer 69. Moreover, loss of the death receptor Fas also inhibits DEN 
induced carcinogenesis 70. Along these lines, knockout murine models of various death 
receptors do not develop spontaneous cancers. Based on this concept, persistent 
hepatocyte apoptosis promotes inflammation and associated compensatory cellular 
proliferation, increasing the risk of hepatic carcinogenesis. Thus abrogating apoptosis in 
chronic liver inflammation by caspase inhibitors should be safe with regard to cancer risk. 
Extrapolation of these interesting findings to human disease states should be carefully 
addressed in future investigations of this class of drugs.  
 
In summary, our results suggest the following scenario of liver protection by Emricasan in 
NASH: in the murine model of HFD diet induced NASH, cell damage or cell death products 
results in the production by inflammatory cells of pro-inflammatory cytokines and 
chemokines, triggering a pro-inflammatory milieu that further increases hepatocyte 
damage and inflammation. This phenomenon activates HSC by phagocytosis of apoptotic 
bodies and releasing of the pro-fibrogenic cytokines by inflammatory cells, thus 
accelerating production of extracellular matrix by collagen-1α, TIMPs and cytokines and 
promoting liver fibrosis of the liver. The pan-caspase inhibitor emricasan was found to 
suppress hepatocyte apoptosis by blocking pro-apoptotic caspases; this decrease in cell 
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damage and the inhibition of pro-inflamatory caspases may then interrupt the 
inflammatory milieu and prevent a pro-fibrogenic process and activation of HSC. 
Therefore, the use of a pan-caspase inhibitor might provide an attractive anti-fibrotic 
therapy in NASH.  
 
TABLES. 
Table 1. Metabolic biochemical profile 
 Reg Chow HFD HFD + Emricasan 
Final weigth (g) 31 ± 1 43 ± 2 ** 42 ± 2 ** 
Glucose (mg/dl) 208 ± 16 302 ± 30 * 281 ± 23 * 
Insulin 
(mU/mL) 17 ± 3  37 ± 4 ** 35 ± 5** 
HOMA-IR 8 ± 3  28 ± 10** 24 ± 8** 
Serum Cholesterol 
(mg/dl) 
68 ± 10 183 ± 25 ** 141 ± 7 ** 
Liver triglycerides 50 ± 5 89 ± 11 * 96 ± 11 * 
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(mg/g) 
Liver cholesterol 
(mg/g) 
5 ± 2 12 ± 2 ** 9± 2 ** 
Values are means ± SD, *  p < 0.05, ** p < 0.001 
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FIGURE LEGENDS 
FIGURE 1. Hepatocyte apoptosis and caspase activation are attenuated in Emricasan 
treated HFD-fed mice. A: Representative photpmicrograoh of TUNEL-stained liver sections 
are shown. B: The number of TUNEL-positive cells (marked with arrows) was quantitated 
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and expressed as apoptotic cells/high-power fields (HPF). C: Apoptosis was also evaluated 
by measuring caspase-3 biochemical activity (Percentage of activity from Reg Chow mice) 
and D: by measuring caspase-8 biochemical activity (Percentage of activity from Reg Chow 
mice). Data are expressed as the mean +/- 95% CI for mean. *p< 0.05. Regular Chow-fed 
mice (C), High Fat Diet-fed mice (HFD) and emricasan treated High Fat Diet-fed mice (HFD 
+ Emricasan). 
 
FIGURE 2. Pan-caspase inhibitor decrease the histopathological NAS score. A: 
Representative hematoxylin-eosin stained sections of the liver at 100X and 400X. Liver 
sections were evaluated using the NAS (Non-alcoholic fatty liver disease Activity Score) 
histological score. Data represent mean ± standard error of the mean.  * p<0.05. Regular 
Chow-fed mice (C), High Fat Diet-fed mice (HFD) and Emricasan treated High Fat Diet-fed 
mice (HFD + Emricasan). 
 
FIGURE 3. Serum markers of liver injury and hepatic oxidative stress are reduced in 
Emricasan treated HFD-fed mice A: Serum AST and B: ALT values were measured. C: 
Hepatic TBARS levels were evaluated, fold change was determined after normalization to 
regular chow fed mice. Data are expressed as the mean +/- 95% CI for mean. * p< 0.05. 
Regular Chow-fed mice (C), High Fat Diet-fed mice (HFD) and Emricasan treated High Fat 
Diet-fed mice (HFD + Emricasan). 
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FIGURE 4. Hepatic inflammatory mediators are reduced in Emricasan treated HFD-fed 
mice A: TNF-alpha mRNA and B: TNF-alpha protein level values were measured by qPCR 
and ELISA. C: MCP-1 mRNA and D: MCP-1 protein level were measured by qPCR and ELISA. 
E: CXCL2 mRNA and F: IL-1β mRNA were quantified by qPCR. Data are expressed as the 
mean +/- 95% CI for mean. *p< 0.05. Regular Chow-fed mice (C), High Fat Diet-fed mice 
(HFD) and Emricasan treated High Fat Diet-fed mice (HFD + Emricasan). 
 
FIGURE 5. HSC Activation is attenuated in Emricasan treated HFD-fed mice. A: mRNA was 
extracted from livers, αSMA mRNA expression, a marker of HSC activation, was quantified 
by qPCR. Fold induction was determined after normalization to Actin. B: Representative 
photomicrographs after immunofluorescence for αSMA are depicted (magnification 
400X). C: morphometric analysis of quantitation αSMA + area is shown. C:  Data are mean 
± standard deviation. Asterisks indicate p<0.05. Regular Chow-fed mice (C), High Fat Diet-
fed mice (HFD) and Emricasan treated High Fat Diet-fed mice (HFD + Emricasan). 
 
FIGURE 6. Pro-fibrogenic cytokine expression is reduced in Emricasan treated HFD-fed 
mice. A: mRNA was extracted from livers and qPCR analyses of hepatic pro-fibrogenic 
cytokines were performed. Fold induction was determined after normalization to Actin. A: 
TGF-β, B: TIMP-1. Data represent mean ± standard deviation. * p<0.05. Regular Chow-fed 
mice (C), High Fat Diet-fed mice (HFD) and Emricasan treated High Fat Diet-fed mice (HFD 
+ Emricasan). 
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FIGURE 7. Liver fibrogenesis is attenuated under pan-caspase inhibitor treatment in 
HFD-fed mice. A: Representative photomicrographs of Mallory's trichrome-stained (top) 
liver sections and Sirius red staining (bottom) a chemical stain of collagen deposition in 
the liver are shown. (magnification 400X) B: Collagen 1 (Coll-1) mRNA expression, marker 
of hepatic fibrogenesis, was quantified using qPCR, Fold induction was determined after 
normalization to Actin. C: Fibrosis was quantified using modified NAS histological score. D: 
Collagen fibers stained with Sirius red were quantified using digital image analysis in 
sinusoidal area. Representative photomicrographs of liver sections (left) are depicted 
(magnification 40X). (E) Hepatic hydroxyproline content. Data represent the mean ± 
standard deviation. * p < 0.05. 
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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